← Issue №3/ week of Jul 19, 2026/Hepatology

Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial.

From GI Signals issue №3: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology rct · n=82 · Jul 23, 2026 · Am J Gastro · IF 9.8

Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial.

New evidencePSCmicrobiome
Clinical takeawayDo not use oral vancomycin for PSC. The biochemical reduction in SAP did not translate to clinically meaningful disease improvement, and a material cosmetic adverse effect was observed. PSC remains without proven medical therapy.
What it foundOral vancomycin reduced SAP by 21.9% versus 1.2% placebo (p=0.03) but did not normalize SAP (6.7% vs 5%, p=1.00), improve Mayo risk score (-0.1 both groups, p=0.88), or change liver stiffness (OV -4.0 kPa vs placebo +0.1 kPa, p=0.15). Tooth and tongue discoloration occurred in 17.5% of OV recipients.
ContextPSC currently lacks approved medical therapies; prior evidence suggested OV as a potential candidate, but this negative phase 3 trial definitively rules it out.
Emergingsuggested applicable standard· American College of Gastroenterology (Kwo PY, Cohen SM, Lim JK), "ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries," Am J Gastroenterol 2017;112(1):18-35

Decision at stakewhether oral vancomycin should be prescribed for primary sclerosing cholangitis

Patients with an elevated ALP, with or without elevated bilirubin, should also be tested for primary sclerosing cholangitis with cholangiography by MRCP (or ERCP) together with serum IgG4, because some extrahepatic cholestatic disease (e.g., PSC, HIV/AIDS cholangiopathy) may not be visible on ultrasound; a history of cholangitis or of colonic inflammatory bowel disease further raises suspicion but is not a prerequisite for obtaining cholangiography.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

An elevated alkaline phosphatase should first be confirmed to be of hepatic origin: confirm with an elevated GGT, or use ALP isoenzyme fractionation or 5'-nucleotidase to separate liver from non-hepatic (e.g., bone) sources. GGT should NOT be used as a standalone screening test in the absence of otherwise-abnormal liver chemistries, and GGT is not specific (elevated in >50% of alcohol users without overt liver disease). Patients with an elevated ALP, with or without elevated bilirubin, should be tested for primary biliary cholangitis with an anti-mitochondrial antibody (AMA). Once ALP is confirmed to be of hepatic origin, obtain a liver ultrasound to assess the hepatic parenchyma and bile ducts: biliary dilatation suggests an extrahepatic cause, while a non-dilated biliary system suggests an intrahepatic cause. Patients with an elevated ALP, with or without elevated bilirubin, should also be tested for primary sclerosing cholangitis with cholangiography by MRCP (or ERCP) together with serum IgG4, because some extrahepatic cholestatic disease (e.g., PSC, HIV/AIDS cholangiopathy) may not be visible on ultrasound; a history of cholangitis or of colonic inflammatory bowel disease further raises suspicion but is not a prerequisite for obtaining cholangiography. Liver biopsy is generally not required; about 80% of isolated ALP elevations can be diagnosed from history, physical exam, routine labs, and chest X-ray.

American College of Gastroenterology (Kwo PY, Cohen SM, Lim JK), "ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries," Am J Gastroenterol 2017;112(1):18-35 · reviewed 2026-07-23 ↗
Eaton JE … Carey EJ · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
← Read the whole of issue №3 Every paper GI Signals surfaces gets a page like this one. All issues